| Literature DB >> 28410415 |
Nicolas Argy1,2,3,4, Eric Kendjo2, Claire Augé-Courtoi3,4, Sandrine Cojean2, Jérôme Clain2,3,4, Pascal Houzé3,5, Marc Thellier6,7, Veronique Hubert2, Philippe Deloron3,4, Sandrine Houzé1,2,3,4.
Abstract
OBJECTIVES: Imported malaria in France is characterized by various clinical manifestations observed in a heterogeneous population of patients such as travelers/expatriates and African migrants. In this population, host factors and parasite biomass associated with severe imported malaria are poorly known.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28410415 PMCID: PMC5391917 DOI: 10.1371/journal.pone.0175328
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Demographic, epidemiological, clinical and biological data from imported malaria cases in Metropolitan France from 2010 to 2013.
| SM (n = 138) | UM (n = 195) | P value | ||
|---|---|---|---|---|
| VSM (n = 55) | MSM (n = 83) | |||
| Demographic data | ||||
| Age (years) | 44.4 ±17 | 36.3 ±14.8 | 35.7 ±16.3 | 0.002 |
| Men | 36 (16.7) | 51 (23.7) | 128 (59.6) | 0.8 |
| Women | 19 (16.1) | 32 (27.1) | 67 (56.8) | |
| Epidemiological data | ||||
| 1st generation migrant | 31 (14.4) | 50 (23.2) | 134 (62.3) | 0.002 |
| 2nd generation migrant | 5 (9.7) | 11 (21.1) | 36 (69.2) | |
| Travelers/expatriates | 19 (28.8) | 22 (33.3) | 25 (37.9) | |
| Country of infection | ||||
| West Africa | 32 (14) | 53 (23.2) | 143 (62.8) | 0.09 |
| Central Africa | 18 (20.4) | 24 (27.3) | 46 (52.3) | |
| East Africa | 1 (20) | 1 (20) | 3 (60) | |
| Indian Ocean | 3 (30) | 4 (40) | 3 (30) | |
| Caribbean | 0 (0) | 1 (100) | 0 (0) | |
| Asia | 1 (100) | 0 (0) | 0 (0) | |
| History of malaria | 8 (11.3) | 13 (18.3) | 50 (70.4) | 0.03 |
| Immunosuppression | 6 (30) | 7 (35) | 7 (35) | 0.06 |
| Onset of symptoms (days) | 3 [0–8] | 3 [0–8] | 3 [0–9] | 0.28 |
| Onset of diagnosis (days) | 4 [2–6] | 3 [2–5] | 3 [2–4] | 0.04 |
| Clinical data | ||||
| Neurological disorders | 30 (55) | 0 (0) | 0 (0) | NA |
| Coma | 1 (2) | 0 (0) | 0 (0) | |
| Shock | 17 (31) | 0 (0) | 0 (0) | |
| Respiratory failure | 7 (13) | 0 (0) | 0 (0) | |
| Hemorrhagic syndrome | 1 (2) | 1 (1) | 0 (0) | |
| Hemoglobinuria | 4 (7) | 7 (9) | 0 (0) | |
| Jaundice | 19 (35) | 12 (15) | 0 (0) | |
| Biological data | ||||
| Platelets (Giga/L) | 37 [21–69] | 66 [42–108] | 96 [64–142] | 0.0001 |
| Parasitemia (103*parasites/μL) | 360 [135–720] | 270 [180–450] | 45 [18–72] | 0.0001 |
| Acidosis (pH<7.35) | 7 (13) | 0 (0) | 0 (0) | NA |
| Lactacidemia (>2.2 mmol/L) | 27 (31) | 0 (0) | 0 (0) | |
| Hyperparasitemia (>180.000 parasites/μL) | 40 (73) | 65 (79) | 0 (0) | |
| Anemia (Hb<8 g/dL) | 3 (5) | 4 (5) | 0 (0) | |
| Creatinine (>265 μmol/L) | 15 (27) | 0 (0) | 0 (0) | |
| Blood glucose (<2.2 mmol/L) | 2 (4) | 0 (0) | 0 (0) | |
| Bilirubinemia (>50μmol/L) | 24 (44) | 14 (58) | 0 (0) | |
SM, severe malaria; VSM, very severe malaria; MSM, moderately severe malaria; UM, uncomplicated malaria; Hb, hemoglobin; NA, not applicable.
Categorical data are presented as absolute numbers (%).
* Chi-square test and Fisher’s exact test were used to compare categorical variables between groups. Significant difference when p<0.05.
†Normally distributed variables are represented by their mean ± standard deviation.
a ANOVA was used to compare parametrics quantitative variables between groups. Significant difference when p<0.05.
§ Existence of a prior self-reported malaria infection.
¶ Immunosuppressive status includes HIV infection (95%) and iatrogenic immunosuppression (5%).
‡ Non-normally distributed data are shown as median [25th percentile-75th percentile].
b Kruskall-Wallis tests was used to compare non-parametrics quantitative variables between groups. Significant difference when p<0.05.
♯ The onset of symptoms is the number of days between the return from endemic regions and the onset of clinical symptoms.
& The onset of diagnosis is the number of days between the onset of symptoms and the diagnosis in hospital. In our cohort, treatment started on the day of diagnosis.
+ Neurological disorders included obnubilation, confusion, drowsiness and prostration [19].
Fig 1PfHRP2 plasma levels and parasite biomass according to clinical presentation of imported malaria.
(A) Log-transformed plasma levels of PfHRP2 in the very severe malaria (VSM), moderately severe malaria (MSM) and uncomplicated malaria (UM) sub-groups. Levels of PfHRP2 were determined on 315 D0 plasma samples by ELISA. (*) corresponds to a significant difference using ANOVA test (p<0.05) and Bonferroni’s correction (p<0.016). (B) Log-transformed estimated total parasite biomass (Ptot), estimated total circulating parasite biomass (Pcirc) and estimated sequestrated parasite biomass (Pseq) respectively in the very severe malaria (VSM) (red box plot), moderately severe malaria (MSM) (orange box plot) and uncomplicated malaria (UM) groups (white box plot). Parasite biomass was estimated for 176 patients using a mathematical approach as described [15] with quantitative plasma levels of PfHRP2 (g/L) determined by ELISA, hematocrit (%), patient body weight (kg) and parasitemia (parasites/μL) on D0 sample. Box plot represents the median [25th percentile-75th percentile] with the extreme value 10th and 90th percentile. (*) corresponds to a significant difference using ANOVA test (p<0.05) and Bonferroni’s correction (p<0.016).
Repartition of antibody titer sub-groups in each epidemiological sub-group.
| FGM | SGM | T/E | P value | |
|---|---|---|---|---|
| No. (%) | No. (%) | No. (%) | ||
| Negative | 39 (41.9) | 23 (24.7) | 31 (33.3) | < 0.001 |
| Positive | 125 (69.8) | 26 (14.5) | 28 (15.6) | |
| Strongly positive | 47 (82.4) | 3 (5,3) | 7 (12.3) |
FGM, first-generation migrants; SGM, second-generation migrants; T/E, Travelers/expatriates.
Patients with negative (<64), positive (between 64 and 1,024) and strongly positive antibody titers (superior or equal to 4,096), as determined by indirect immunofluorescence assay, are represented in percent (%) for each epidemiological sub-group.
(*) χ2 and Fischer’s exact test when appropriate were used to compare categorical variables between epidemiological sub-groups. Significant difference was considered when p<0.05.
Multivariate analysis with logistic regression to identify factors influencing positive serology at D0 in French imported malaria.
| Positive serology | Variable | Odds Ratio | [95% CI] | P value |
|---|---|---|---|---|
| Age<18 years | 1.00 (reference group) | |||
| Age>18 years | 0.8 | [0.3–2.2] | 0.7 | |
| MSM | 1.00 (reference group) | |||
| UM | 2.2 | [1.2–4] | 0.008 | |
| VSM | 2.1 | [1–4.6] | 0.06 | |
| FGM | 1.00 (reference group) | |||
| SGM | 0.3 | [0.1–0.6] | 0.002 | |
| T/E | 0.3 | [0.2–0.5] | <0.001 |
VSM, very severe malaria; MSM, moderately severe malaria; UM, uncomplicated malaria; FGM, first-generation migrants; SGM, second-generation migrants; T/E, travelers/expatriates; CI, confidence interval.
Multivariate analysis was performed on 329 patients and age (as a binary variable: <18 years-old or >18 years-old), clinical sub-group (VSM, MSM, UM) and epidemiological sub-groups (FGM, SGM and T/E) were selected, as theoretical influent factors (age) or after univariate analysis (clinical and epidemiological sub-groups). Age< 18 years old, MSM and FGM were chosen as reference groups. Factors were considered to have a significant influence if p value<0.05.
Models of multivariate analysis with linear regression to identify factors related to PfHRP2, estimated total parasite biomass, estimated total circulating parasite biomass and estimated sequestered parasite biomass in imported malaria in France, 2010–2013.
| Model | Risk factors | Coefficient (standard error) | [95% CI] | P value | |
|---|---|---|---|---|---|
| Model 1: PfHRP2 | Intercept | 7 (0.44) | [6.1–7.9] | < 0.0001 | |
| Age | 0.0007 (0.008) | [-0.01–0.01] | 0.93 | ||
| Disease severity sub-groups | |||||
| VSM | 0.6 (0.3) | [-0.08–1.2] | 0.09 | ||
| UM | -1.6 (0.25) | [-2.1- -1.2] | <0.001 | ||
| Epidemiological sub-groups | |||||
| SGM | 0.4 (0.3) | [-0.3–1.1] | 0.22 | ||
| T/E | 0.5 (0.3) | [-0.01–1.1] | 0.06 | ||
| Antibody titer sub-groups | |||||
| Positive | -0.3 (0.3) | [-0.9–0.2] | 0.23 | ||
| Negative | -0.96 (0.3) | [-1.6- -0.3] | 0.004 | ||
| Model 2: Ptot | Intercept | 28.5 (0.4) | [27.6–29.3] | < 0.0001 | |
| Age | 0.002 (0.01) | [-0.02–0.02] | 0.83 | ||
| Disease severity sub-groups | |||||
| VSM | 0.5 (0.4) | [-0.3–1.2] | 0.23 | ||
| UM | -1.7 (0.3) | [-2.4- -1.1] | <0.001 | ||
| Epidemiological sub-groups | |||||
| SGM | -0.3 (0.4) | [-1.2–0.6] | 0.52 | ||
| T/E | 0.3 (0.4) | [-0.5–1.0] | 0.48 | ||
| Antibody titer sub-groups | |||||
| Positive | -0.7 (0.4) | [-1.5–0.07] | 0.08 | ||
| Negative | -1.1 (0.4) | [-2.0- -0.3] | 0.009 | ||
| Model 3: Pcirc | Intercept | 26.5 (0.3) | [25.9–27.1] | < 0.0001 | |
| Age | 0.02 (0.01) | [0.004–0.03] | 0.01 | ||
| Disease severity sub-groups | |||||
| VSM | -0.1 (0.2) | [-0.6–0.3] | 0.55 | ||
| UM | -2.1 (0.2) | [-2.5- -1.7] | <0.001 | ||
| Epidemiological sub-groups | |||||
| SGM | -0.3 (0.3) | [-0.9–0.22] | 0.23 | ||
| T/E | 0.1 (0.2) | [-0.3–0.6] | 0.61 | ||
| Antibody titer sub-groups | |||||
| Positive | 0.5 (0.2) | [0.001–0.98] | 0.049 | ||
| Negative | 0.5 (0.3) | [-0.006–1.1] | 0.052 | ||
| Model 4: Pseq | Intercept | 26.5 (2.9) | [21–32.2] | < 0.0001 | |
| Age | -0.08 (0.07) | [-0.2–0.05] | 0.23 | ||
| Disease severity sub-groups | |||||
| VSM | 6.5 (2.5) | [1.6–11.5] | 0.01 | ||
| UM | 1.2 (2.1) | [-2.9–5.2] | 0.6 | ||
| Epidemiological sub-groups | |||||
| SGM | -0.4 (2.9) | [-6.0–5.3] | 0.9 | ||
| T/E | 1.9 (2.4) | [-2.8–6.6] | 0.42 | ||
| Antibody titer sub-groups | |||||
| Positive | -6.7 (2.5) | [-11.6- -1.7] | 0.009 | ||
| Negative | -7.8 (2.8) | [-13.2- -2.3] | 0.005 |
VSM, very severe malaria; MSM, moderately severe malaria; UM, uncomplicated malaria; FGM, first-generation migrants; SGM, second-generation migrants; T/E, travelers/expatriates; CI, confidence interval.
A linear regression was performed on 315 patients for PfHRP2 and on 176 patients for Ptot, Pcirc and Pseq. Age, disease severity sub-group (VSM, MSM, UM), epidemiological sub-group (FGM, SGM, T/E) and antibody titer sub-groups (negative, positive, strongly positive) were selected as potential factors after univariate analysis. MSM, FGM and strongly positive antibody titer sub-groups were chosen as reference. PfHRP2, Ptot, Pcirc, Pseq were log-transformed for statistical analysis. Significance was set to p<0.05.